# An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

> clinical trial · VERIFIED · 2026-08-04

Status: RECRUITING · Sponsor: Novartis Pharmaceuticals · Condition: Relapsing Multiple Sclerosis

- Company: Novartis Pharmaceuticals
- Sector: therapeutics
- Primary source: https://clinicaltrials.gov/study/NCT06617793

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.